RESEARCH PAPER
Lack of major impact of implementation of the Advanced Hybrid Closed Loop System in technologically-naïve patients with Type 1 Diabetes mellitus on their food choices or weight – a one year follow-up
More details
Hide details
1
University Hospital in Krakow, Poland
2
Department of Metabolic Diseases, Jagiellonian University Medical College, Krakow, Poland
3
Department of Psychiatry, Jagiellonian University Medical College, Krakow, Poland
4
Clinical Provincial Hospital of Frederic Chopin No. 1 in Rzeszów, Poland
5
College of Medical Sciences, University of Rzeszów, Poland
Corresponding author
Sabina Krzyżowska
Hospital University in Krakow, Jakubowskiego 2, 30-688, Krakow, Poland
Ann Agric Environ Med. 2023;30(3):468-473
KEYWORDS
TOPICS
ABSTRACT
Introduction and objective:
The purpose of this follow-up study on the implementation of advanced closed-loop hybrid insulin pumps in people with type 1 diabetes was to assess the impact of introducing this advanced technology on quantitative and qualitative parameters of diet.
Material and methods:
18 patients (8 women and 10 men, mean age 40.9 years) patients using the CE-marked MiniMed 780G AHCL system who completed 1 year of follow-up were included into the study. The research tool was the KomPAN questionnaire with several own questions added, asked in three study periods, concerning the number of meals consumed, general and night snacking, carbohydrate counting, frequency of consumption of various groups of products that affect postprandial glycaemia.
Results:
Although the mean body weight of the examined group did not increase significantly (from 75.1 kg at the beginning to 75,9 kg at the end), five various individual scenarios of weight change were observed. The eating habits has not changed, but patients began to consume less products containing simple sugars, e.g. fruit preserves, milk chocolate or fish in sauces (p<0.05). No statistically significant correlation was found between the change in body weight at the end of the study and the average amount of carbohydrates entered into the pump from the entire 12 months (p = 0.460).
Conclusions:
The implementation of AHCL system in technology naïve patients, despite offering more freedom of food choices due to better glycaemic control, did not have a significant impact on patients’ dietary patterns, also did not result in weight gain. This is important since AHCL system offers more freedom of food choices due to better glycaemic control. However, the longer follow up and the study based on larger population is required to finally address the issue of the impact of AHCL on body mass.
REFERENCES (27)
1.
Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [published correction appears in Diabetologia. 2022 Jan;65(1):255]. Diabetologia. 2021;64(12):2609–2652. doi:10.1007/s00125-021-05568-3.
2.
Rawshani A, Rawshani A, Franzén S, et al. Range of Risk Factor Levels: Control, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. Circulation. 2017;135(16):1522–1531. doi:10.1161/CIRCULATIONAHA.116.025961.
3.
Rawshani A, Rawshani A, Sattar N, et al. Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. Circulation. 2019;139(16):1900–1912. doi:10.1161/CIRCULATIONAHA.118.037454.
4.
Foster NC, Beck RW, Miller KM, et al. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018 [published correction appears in Diabetes Technol Ther. 2019 Apr;21(4):230]. Diabetes Technol Ther. 2019;21(2):66–72. doi:10.1089/dia.2018.0384.
5.
Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015;38(6):971–978. doi:10.2337/dc15-0078.
6.
Fuchs J, Hovorka R. Closed-loop control in insulin pumps for type-1 diabetes mellitus: safety and efficacy. Expert Rev Med Devices. 2020;17(7):707–720. doi:10.1080/17434440.2020.1784724.
7.
Janez A, Battelino T, Klupa T, et al. Hybrid Closed-Loop Systems for the Treatment of Type 1 Diabetes: A Collaborative, Expert Group Position Statement for Clinical Use in Central and Eastern Europe. Diabetes Ther. 2021;12(12):3107–3135. doi:10.1007/s13300-021-01160-5.
8.
Matejko B, Juza A, Kieć-Wilk B, et al. Transitioning of People With Type 1 Diabetes From Multiple Daily Injections and Self-Monitoring of Blood Glucose Directly to MiniMed 780G Advanced Hybrid Closed-Loop System: A Two-Center, Randomized, Controlled Study. Diabetes Care. 2022;45(11):2628–2635. doi:10.2337/dc22-0470.
9.
Petrovski G, Al Khalaf F, Campbell J, Fisher H, Umer F, Hussain K. 10-Day structured initiation protocol from multiple daily injection to hybrid closed-loop system in children and adolescents with type 1 diabetes. Acta Diabetol. 2020;57(6):681–687. doi:10.1007/s00592-019-01472-w.
10.
Wądołowska L, Stasiewicz B. Procedura opracowania danych żywieniowych z kwestionariusza KomPAN®. Rozdz. 3. In: KomPAN® Kwestionariusz do badania poglądów i zwyczajów żywieniowych oraz procedura opracowania danych. Gawęcki J, editor. Warszawa: Wyd. Komitetu Nauki o Żywieniu Człowieka Polskiej Akademii Nauk; 2020. p. 35–54.
11.
Akturk HK, Giordano D, Champakanath A, Brackett S, Garg S, Snell-Bergeon J. Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes. Diabetes Obes Metab. 2020;22(4):583–589. doi:10.1111/dom.13933.
12.
Franco L, Bozzetto L, Angelis R, et al. Beneficial effects on body weight of group vs individual care in adults with type 1 diabetes on advanced technologies. Health Sci Rep. 2021;4(4):e385. Published 2021 Oct 1. doi:10.1002/hsr2.385.
13.
Lawton J, Blackburn M, Rankin D, et al. The impact of using a closed-loop system on food choices and eating practices among people with Type 1 diabetes: a qualitative study involving adults, teenagers and parents. Diabet Med. 2019;36(6):753–760. doi:10.1111/dme.13887.
14.
Oh R, Gilani B, Uppaluri KR. Low Carbohydrate Diet. In: StatPearls. Treasure Island (FL): StatPearls Publishing; July 11, 2022.
15.
Corbin KD, Driscoll KA, Pratley RE, et al. Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms. Endocr Rev. 2018;39(5):629–663. doi:10.1210/er.2017-00191.
16.
De Ridder F, den Brinker M, De Block C. The road from intermittently scanned glucose monitoring to hybrid closed-loop systems: Part A. Keys to success: subject profiles, choice of systems, education. Ther Adv Endocrinol Metab. 2019;10:2042018819865399. Published 2019 Jul 25. doi:10.1177/2042018819865399.
17.
Peters AL, Ahmann AJ, Battelino T, et al. Diabetes Technology-Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(11):3922–3937. doi:10.1210/jc.2016-2534.
18.
Knebel T, Neumiller JJ. Medtronic MiniMed 670G Hybrid Closed-Loop System. Clin Diabetes. 2019;37(1):94–95. doi:10.2337/cd18-0067.
19.
Weaver KW, Hirsch IB. The Hybrid Closed-Loop System: Evolution and Practical Applications. Diabetes Technol Ther. 2018;20(S2):S216-S223. doi:10.1089/dia.2018.0091.
20.
Haidar A, Yale JF, Lovblom LE, et al. Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non-inferiority, crossover pilot trial. Diabetes Obesity Metab. 2021 Jun;23(6):1272–1281. doi: 10.1111/dom.14335. PMID: 33528904.
21.
Vaz EC, Porfírio GJM, Nunes HRC, Nunes-Nogueira VDS. Effectiveness and safety of carbohydrate counting in the management of adult patients with type 1 diabetes mellitus: a systematic review and meta-analysis. Arch Endocrinol Metab. 2018;62(3):337–345. doi:10.20945/2359-3997000000045.
22.
Tornese G, Carletti C, Giangreco M, Nistico D, Faleschini E, Barbi E. Carbohydrate Tolerance Threshold for Unannounced Snacks in Children and Adolescents With Type 1 Diabetes Using an Advanced Hybrid Closed-Loop System. Diabetes Care. 2022;45(6):1486–1488. doi:10.2337/dc21-2643.
23.
Sherr JL, Buckingham BA, Forlenza GP, et al. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. Diabetes Technol Ther. 2020;22(3):174–184. doi:10.1089/dia.2019.0286.
24.
Malone SK, Peleckis AJ, Grunin L, et al. Characterizing Glycemic Control and Sleep in Adults with Long-Standing Type 1 Diabetes and Hypoglycemia Unawareness Initiating Hybrid Closed Loop Insulin Delivery. J Diabetes Res. 2021;2021:6611064. Published 2021 Feb 12. doi:10.1155/2021/6611064.
25.
Cyranka K, Matejko B, Juza A, et al. Improvement of Selected Psychological Parameters and Quality of Life of Patients With Type 1 Diabetes Mellitus Undergoing Transition From Multiple Daily Injections and Self-Monitoring of Blood Glucose Directly to the MiniMed 780G Advanced Hybrid Closed-Loop System: Post hoc Analysis of a Randomized Control Study. JMIR Form Res. 2023;7:e43535. Published 2023 Jan 24. doi:10.2196/43535.
26.
Ruszkiewicz K, Jagielski P, Traczyk I. Glycemic control and awareness among diabetic patients of nutrition recommendations in diabetes. Rocz Panstw Zakl Hig. 2020;71(2):191–196. doi:10.32394/rpzh.2020.0116.
27.
Vetrani C, Calabrese I, Cavagnuolo L, et al. Dietary determinants of postprandial blood glucose control in adults with type 1 diabetes on a hybrid closed-loop system. Diabetol. 2022;65(1):79–87. doi:10.1007/s00125-021-05587-0.